43 results about "Erythrocyte binding" patented technology

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPα / CD47 axis. The agent is a human SIRPα fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRPα, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRPα. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.The resulting fusion peptide being exemplified asNH2-CD4-GBP130-COOH1-371 201-774Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.

The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.

CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPα / CD47 axis. The agent is a human SIRPα fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRPα, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRPα. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.

Hybrid peptides capable of binding a blood borne virus to a red cell, comprising a viral binding peptide component and a malaria merozoite red cell peptide binding component.

A method of preparing a bone graft. Mixing bone marrow aspirate with an effective amount of a binding reagent that is capable of binding with red blood cells in the bone marrow aspirate. The bound red blood cells are aggregated. The aggregated bound red blood cells are separated from the bone marrow aspirate to provide a supernatant. At least a portion of the supernatant is associated with an osteoconductive matrix to form the bone graft.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.

CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPα / CD47 axis. The agent is a human SIRPα fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRPα, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRPα. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.

The invention relates to an SPA-antibody tripolymer, a cell treating kit containing the tripolymer, a preparation method and application thereof. The tripolymer comprises an anti erythrocyte antibody, an SPA and an antibody of a certain anti leukocyte antigen or other antigens. The tripolymer is combined with an erythrocyte through the anti erythrocyte antibody per se, the other antibody is combined with a corresponding leukocyte antigen (or other antigens), and then leukocyte (other cells, factors) and the erythrocyte are deposited through an erythrocyte sedimentation process or other methods of density gradient centrifugation and the like, thereby achieving the purpose of eliminating ingredients of corresponding cells and the like, connecting the erythrocyte with a corresponding antigen by the SPA, and being used as a mean for detecting a certain antigen. The invention has convenience and simpleness, and can be directly used for clinically separating and extracting stem cells / progenitor cells; and the collected and extracted stem cells / progenitor cells have no external markers. Meanwhile, the kit based on the tripolymer can be industrially produced so as to realize the popularization of the separation and purification technology of hematopoietic stem cells.

Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.

The invention relates to a method for detecting causal agent and left drug in whole animal blood, wherein it uses gene engineering method or chemical couple method to couple the causal agent antigen, causal agent antibody, drug antibody with single chain antibody or single colon antibody of red blood cell to obtain one dual-function agent which can combine red blood cell and combine causal agent antigen, causal agent antibody, and left drug antibody. The inventive agent can use the red blood cell of animal as instructor to detect the causal agent and left drug of animal.

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.

The invention relates to a maternal fetal blood group incompatibility antibody adsorption therapeutic apparatus in the field of medical science. The therapeutic apparatus is characterized in that Rh positive O-shaped red blood cells are cleaned by 4 DEG C and 37 DEG C normal saline and alternately washed by 25 and 35mmol / L of PB lysate with PH (potential of hydrogen) 7.4, D antigen containing ghost cells without hemoglobin are prepared, 80% cell concentration is formed by the aid of red blood cell storage solution with 3.5% mannitol, the ghost cells are placed in a cylindrical adsorber made of high-biocompatibility materials, sealed and stored at the temperature of 4 DEG C, and a screen is arranged at an outlet of the adsorber to form a defense line for preventing cell fragments from filtration. After plasma is filtered, Rh antibodies are combined into fixed complexes by the Rh positive red blood cells, the broken red blood cell fragments and macromolecular complexes formed by combination are intercepted by the screen of the adsorber, the plasma without morbid substances is filtered from the adsorber and then returned, and group incompatibility is treated by removing the Rh antibodies in the plasma.

The invention relates to a kit and use of SPA (staphylococcal protein A)-antibody trimer. The antibody trimer is formed by an anti erythrocyte antibody, SPA and antibodies of some anti-leukocyte antigen or other antigens. According to the antibody trimer, the self anti erythrocyte antibody is combined with erythrocyte, the other antibody is combined with corresponding leukocyte antigen (or other antigen), then leukocyte (or other cell, factor) and erythrocyte are deposited by a blood sedimentation process or methods, such as density gradient centrifugation to achieve the purpose of eliminating components of corresponding cell and the like, and the erythrocyte can be also connected with corresponding antigen by virtue of the SPA to be used as means for detecting certain antigens. The kit is convenient and simple and can be directly used for clinical separation and extraction of stem cells / progenitor cells, and the collected and extracted stem cells / progenitor cells do not have any foreign markers. The kit based on the trimer can be industrially produced to realize popularization of human hematopoietic stem cell separation and purification technology.

The present invention is one kind of 175 kD recombinant protein (PfEBA175-IIF2) of plasmodium falciparum erythrocyte conjugated antigen functional region, its coding DNA sequence, vector containing the DNA sequence, host cell containing the vector, gene engineering process of preparing the recombinant protein, and the application of the recombinant protein in preparing malaria resisting vaccine and performing preclinical research on plasmodium invasion mechanism. The recombinant protein PfEBA175-IIF2 possesses excellent immunogenicity and good bionomics as well as the function of combining with sialic acid dependent erythrocyte, and can initiate effective plasmodium resisting immune response in immunized individuals.

A blood testing method for use in the detection of a disease, wherein at least one characteristic antibody or complement factor is bound to a subject's red blood cells, comprises providing a microarray wherein a plurality of binding agents therefor are immobilized on a substrate at discrete pre-defined positions; and contacting a blood sample therewith. The presence of bound red blood cells is then detected.

The invention discloses a recombination protein for detection of virus of porcine reproductive and respiratory syndrome, which is a fusion gene code spliced by a single-chain antibody gene resisting surface H antigen of human red blood cell and a single-chain antibody gene resisting the virus of porcine reproductive and respiratory syndrome. The recombination protein has dual functions of being capable of both combining with human red blood cell without agglutinating and combining with the virus of porcine reproductive and respiratory syndrome, and has observable agglutination phenomenon under action of virus bridging. The recombination protein prepared by the method can be used for detecting virus of porcine reproductive and respiratory syndrome, is simple to operate, has high sensitivity and strong specificity, and meets the requirement of base site on rapidness and simpleness and convenience.

The invention relates to a human Rh positive red blood cell adsorber in the field of medical science. The adsorber is characterized in that fresh Rh positive O-shaped red blood cells are cleaned by 4 DEG C and 37 DEG C normal saline, immune antibodies or natural antibodies attached to surfaces of the red blood cells are removed, the cells are deposited in the cylindrical adsorber made of high-biocompatibility materials by 4 / 5, 3.5% mannitol red blood cell storage solution is added, so that the concentration of the red blood cells reaches 80%, the red blood cells are jogged, blended, sealed, stored at the temperature of 4 DEG C and used at regular intervals, and a screen is arranged at an inlet of a purifier to form a defense line for preventing cell fragments from filtration. After plasma is filtered, Rh antibodies are combined into fixed complexes by the Rh positive red blood cells, the broken red blood cell fragments and macromolecular complexes formed by combination are intercepted by the screen of the purifier, the plasma without morbid substances is filtered from the purifier and then returned, and group incompatibility is treated by removing the Rh antibodies in the plasma.

The invention discloses a functional polypeptide, an erythrocyte drug-loading system capable of being specifically bound with collagen and application of the erythrocyte drug-loading system. The functional polypeptide comprises a collagen binding sequence and an erythrocyte binding peptide sequence connected with the collagen binding sequence. The functional polypeptide has an amino acid sequenceas shown in SEQ ID NO: 1. The erythrocyte drug-loading system capable of being specifically bound with the collagen comprises drug-loading erythrocytes and functional polypeptides specifically bound with the drug-loading erythrocytes. The constructed erythrocyte drug-loading system capable of being specifically bound with the collagen can effectively anchor drug-loading erythrocyte microspheres onthe collagen material, so that rapid loss of a drug after transplantation is reduced; the drug-loading system has the capability of realizing concentration maintenance and slow release capabilities of the drug at a local injury part, can prolong a half-life period of the drug, promote more neural stem cells to be differentiated into neurons, promote more axonal regeneration, and has the functionof promoting better movement recovery of spinal cord injuries.

The invention relates to the technical field of blood detection quality control substances, in particular to a reticulocyte quality control substance preparation method based on a fluorescence principle, which comprises the following steps: washing and separating anticoagulant blood to obtain seedless red blood cells; treating and fixing the seedless red blood cells by using a cell curing agent to obtain cured red blood cells; performing curing agent removal treatment on the cured red blood cells to obtain red blood cell products; the erythrocyte product is washed and then stored in a cell maintenance solution, a reticulocyte simulant is obtained, the reticulocyte quality control material is prepared by combining the prepared reticulocyte simulant with erythrocytes, and the problems that when the reticulocytes are prepared, a protein fluorescent dye needs to be used for dyeing the cells, and the dyeing time is short are solved. And the manufacturing cost is increased.

The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.

The present invention provides isolated polynucleotides, polypeptides, antibodies and / or vaccines for the prevention and / or treatment of malaria caused by Plasmodium falciparum and / or Plasmodium vivax. In particular, the polypeptide fragments are derived from the binding domain of the reticulocyte binding proteins of Plasmodium falciparum and / or Plasmodium vivax. The present invention also provides recombinant vaccines and their use in the prevention and / or treatment of malaria.

The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.

The present invention is one kind of 175 kD recombinant protein (PfEBA175-IIF2) of plasmodium falciparum erythrocyte conjugated antigen functional region, its coding DNA sequence, vector containing the DNA sequence, host cell containing the vector, gene engineering process of preparing the recombinant protein, and the application of the recombinant protein in preparing malaria resisting vaccine and performing preclinical research on plasmodium invasion mechanism. The recombinant protein PfEBA175-IIF2 possesses excellent immunogenicity and good bionomics as well as the function of combining with sialic acid dependent erythrocyte, and can initiate effective plasmodium resisting immune response in immunized individuals.

The invention discloses a 3F3Rmg recombinant fusion protein and a preparation method thereof. The recombinant fusion protein is encoded by a 3F3Rmg fusion gene obtained by splicing a 3F3ScFv gene and an Rmg gene, and has a base sequence shown in a sequence table SEQ.ID.No.1. Due to the difunctional characteristic of the 3F3Rmg recombinant fusion protein, the fusion protein can be combined with a human red blood cell without being agglutinated, can react with a rabies G antibody, and undergoes an agglutination phenomenon which can be observed by naked eyes under an antibody bridging action. A dog rabies antibody red cell agglutination test diagnostic reagent kit prepared by applying the recombinant fusion protein is easy to operate, has high sensitivity and high specificity, is particularly suitable for detecting the dog rabies antibody, and meets the requirements of use rapidness, easiness and convenience for a substrate field.